close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ADC Therapeutics SA Common Shares (NY:ADCT)

3.625 -0.035 (-0.96%)
Streaming Delayed Price Updated: 10:07 AM EST, Jan 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ADC Therapeutics SA Common Shares

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
ADC Therapeutics Provides Business Updates
From ADC Therapeutics SA
Via GlobeNewswire
News headline image
ADC Therapeutics Announces Initial Results from Investigator-Initiated Phase 2 Clinical Trial Evaluating ZYNLONTA® in Combination with Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma (FL)
From ADC Therapeutics SA
Via GlobeNewswire
News headline image
Analyst Expectations for ADC Therapeutics's Future ↗
 
Via Benzinga
News headline image
ADC Therapeutics Receives NYSE Notice of Non-Compliance With Continued Listing Standards
From ADC Therapeutics SA
Via GlobeNewswire
News headline image
The Latest Analyst Ratings for ADC Therapeutics ↗
 
Via Benzinga
News headline image
A Preview Of ADC Therapeutics's Earnings ↗
 
Via Benzinga
News headline image
4 Analysts Have This to Say About ADC Therapeutics ↗
 
Via Benzinga
News headline image
ADC Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates
From ADC Therapeutics SA
Via GlobeNewswire
News headline image
Why BEST Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket ↗
Gainers Carbon Revolution Public Limited (NASDAQ: CREV) shares surged 358% to $134.37 in pre-market trading after gaining 100% on Friday. The company’s stock began trading on Friday following merger... 
Via Benzinga
News headline image
ADC Therapeutics to Participate in the Jefferies London Healthcare Conference
From ADC Therapeutics SA
Via GlobeNewswire
News headline image
ADC Therapeutics Announces Abstracts Accepted for Presentation at the 65th ASH Annual Meeting
From ADC Therapeutics SA
Via GlobeNewswire
News headline image
ADC Therapeutics to Host Third Quarter 2023 Financial Results Conference Call on November 7, 2023
From ADC Therapeutics SA
Via GlobeNewswire
News headline image
ADC Therapeutics to Participate in September Investor Conferences
From ADC Therapeutics SA
Via GlobeNewswire
News headline image
ADC Therapeutics Announces Updates on ZYNLONTA® LOTIS Clinical Trial Programs at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023)
From ADC Therapeutics SA
Via GlobeNewswire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For August 10, 2023 ↗
 
Via Benzinga
News headline image
ADC Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Updates
From ADC Therapeutics SA
Via GlobeNewswire
News headline image
ADC Therapeutics to Host Second Quarter 2023 Financial Results Conference Call on August 8, 2023
From ADC Therapeutics SA
Via GlobeNewswire
News headline image
Stocks That Hit 52-Week Lows On Tuesday ↗
  On Tuesday, 56 companies set new 52-week lows. 
Via Benzinga
News headline image
Overland ADCT BioPharma Announces NMPA Accepts Biologics License Application and Grants Priority Review for ZYNLONTA® for Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma
From ADC Therapeutics SA
Via GlobeNewswire
News headline image
Stocks That Hit 52-Week Lows On Monday ↗
  On Monday morning, 70 companies achieved new lows for the year. 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Friday ↗
  On Friday, 54 companies hit new 52-week lows. 
Via Benzinga
News headline image
ADC Therapeutics Pulls Plug On Mid-Stage Zynlonta Study In Untreated Lymphoma Patients After Patient Deaths ↗
ADC Therapeutics SA (NASDAQ: ADCT) announced that it plans to discontinue the Phase 2 LOTIS-9 trial evaluating Zynlonta (loncastuximab tesirine-lpyl) and rituximab in unfit or frail patients with... 
Via Benzinga
News headline image
ADC Therapeutics Announces Plan to Discontinue the Phase 2 LOTIS-9 Clinical Trial of ZYNLONTA® (loncastuximab tesirine-lpyl) and Rituximab in Unfit or Frail Previously Untreated DLBCL Patients
From ADC Therapeutics SA
Via GlobeNewswire
News headline image
Dow Rises More Than 200 Points; Adial Pharmaceuticals Shares Spike Higher ↗
U.S. stocks traded higher toward the end of trading, with the Dow Jones surging more than 200 points on Tuesday. The Dow traded up 0.73% to 34,193.60 while the NASDAQ rose 0.25% to 13,720.16. The S&P... 
Via Benzinga
News headline image
Why Siyata Mobile Shares Are Trading Lower By 21%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
Gainers CytoMed Therapeutics Limited (NASDAQ: GDTC) shares climbed 129.5% to $8.01 after gaining 9% on Monday. 
Via Benzinga
News headline image
Crude Oil Rises 2%; ADC Therapeutics Shares Plummet ↗
U.S. stocks traded higher midway through trading, with the Dow Jones surging over 100 points on Tuesday. The Dow traded up 0.41% to 34,082.47 while the NASDAQ rose 0.29% to 13,725.52. The S&P 500, also... 
Via Benzinga
News headline image
Dow Jumps Over 100 Points; US Small Business Optimism Index Tops Estimates ↗
U.S. stocks traded higher this morning, with the Dow Jones gaining over 100 points on Tuesday. Following the market opening Tuesday, the Dow traded up 0.40% to 34,080.13 while the NASDAQ rose 0.23% to... 
Via Benzinga
News headline image
ADC Therapeutics Stock Is Plunging Today - What's Going On? ↗
ADC Therapeutics SA (NASDAQ: ADCT) has voluntarily paused enrollment of new patients in the Phase 2 LOTIS-9 trial evaluating Zynlonta (loncastuximab tesirine-lpyl) and rituximab (Lonca-R) in unfit or... 
Via Benzinga
News headline image
ADC Therapeutics Announces Voluntary Pause of Enrollment in the Phase 2 LOTIS-9 Clinical Trial of ZYNLONTA® (loncastuximab tesirine-lpyl) and Rituximab in Unfit or Frail Previously Untreated DLBCL Patients
From ADC Therapeutics SA
Via GlobeNewswire
News headline image
ADC Therapeutics Announces Updated LOTIS-2 Results Demonstrating Durable, Long-Term Responses of ZYNLONTA® in Relapsed/Refractory DLBCL
Data being presented at the EHA 2023 Hybrid Congress will also be highlighted in an encore oral presentation at 17-ICML 
From ADC Therapeutics SA
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today